Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: A case series study;

Autores organización

• Viviana Viviana Parra Izquierdo

  Autor

• Maria Consuelo Romero Sanchez

  Autor

Autores

• Frías-Ordoñez JS
• Juliao-Baños F
• Cuadros C
• Flórez-Sarmiento C

Grupos de investigación

• Grupo de Inmunología celular y molecular Universidad El Bosque (InmuBo)

  Investigador

  Maria Consuelo Romero Sanchez

Resumen

Introduction: Tofacitinib is indicated in patients with moderate to severe ulcerative colitis (UC); however, given its rapid onset of action, it may constitute an alternative in patients with hospitalized severe acute UC. There are few data on this indication in the literature. The aim of this study was to describe the efficacy and safety of tofacitinib in the management of patients with hospitalized UC, as well as its clinical characteristics and other treatment patterns. Materials and methods: Descriptive observational study of adults and children with CUAG treated with tofacitinib between June 2019 and December 2022 in Colombia. Sociodemographic and clinical variables were collected, therapeutic response was evaluated in different periods of time and descriptive analysis of quantitative and qualitative variables was performed. Results: Six patients (five adults and one pediatric), mean age 33.2 (SD: 8.5) years, with CUAG. Symptom remission was obtained in 100% of patients at day 7 after tofacitinib initiation. In three patients information was obtained beyond 6 months, with 100% clinical, biochemical, and endoscopic remission and without requiring colectomy. In the case of the pediatric patient, symptom remission was achieved one week after starting tofacitinib, remaining in clinical, biochemical and endoscopic remission beyond 6 months. No serious adverse events were reported in any of the cases. Conclusions: Tofacitinib represents a rescue therapeutic alternative in CUAG, with rapid clinical response, adequate tolerance and less need for colectomy, being sustained for periods beyond 6 months. © 2023 Elsevier España, S.L.U.

Copyright © 2023 Elsevier España, S.L.U. All rights reserved.

Keywords

• Disease management; Inflammatory bowel diseases; Janus kinase inhibitors; Therapeutics; Tofacitinib; Ulcerative colitis